| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-06-26 | Aduro Biotech (USA - CA) | nomination |
Nomination | |||
| 2015-06-26 | Flamel Technologies (France) | nomination |
Nomination | |||
| 2015-06-26 | DBV Technologies (France) | nomination |
Allergic diseases | Nomination | ||
| 2015-06-26 | Oncurious (Belgium) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-06-25 | Aegerion Pharmaceuticals (USA - MA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-06-25 | Ultragenyx Pharmaceutical (USA - CA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-06-25 | Illumina (USA - CA) | opening of new premises |
Technology - Services | Opening of new premises | ||
| 2015-06-25 | Novasep (France) | Antibody Drug Conjugate (ADC) facility at the Le Mans site | construction of a production plant |
Technology - Services | Construction of a production plant | |
| 2015-06-25 | Auris Medical (Switzerland) | AM-111 | patients with residual hearing who are undergoing cochlear implant surgery | clinical research |
Otorhinolaryngology | Clinical research agreement |
| 2015-06-24 | Ayoxxa Biosystems (Germany) Grünenthal (Germany) | pain | R&D |
CNS diseases | R&D agreement | |
| 2015-06-23 | AstraZeneca (UK) BIND Therapeutics (USA - MA) | Accurin™ | undisclosed cancer | R&D |
Cancer - Oncology | Milestone |
| 2015-06-23 | Affimed (Germany) | establishment of a new subsidiary in the US |
Cancer - Oncology | Establishment of a new subsidiary in the US | ||
| 2015-06-22 | ReNeuron (UK) Benitec Pharma (Australia) | CTX-derived exosomes | lung cancer and other drug resistant cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2015-06-22 | Intercept Pharmaceuticals (USA - NY) | nomination |
Nomination | |||
| 2015-06-22 | Ultragenyx Pharmaceutical (USA - CA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-06-22 | Santhera Pharmaceuticals (Switzerland) | nomination |
Nomination | |||
| 2015-06-22 | bluebird bio (USA - MA) Kite Pharma (USA - CA) | second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein | Human papillomavirus (HPV) associated cancers (cervical cancers, urogenital cancers) | collaboration development commercialisation |
Cancer - Oncology - Infectious diseases | Collaboration agreement |
| 2015-06-22 | Clovis Oncology (USA - CO) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-06-22 | ADC Therapeutics (Switzerland) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-06-22 | Bind Therapeutics (USA - MA) | nomination |
Cancer - Oncology | Nomination |
